Business
Results of Placing and Subscription
Results of Placing and Subscription.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 1647V Allergy Therapeutics PLC 19 July 2018 \n\nTHIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE RUSSIAN FEDERATION OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL. \nFURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND SHALL NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR THE SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE ANY ORDINARY SHARES OF THE COMPANY IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT SHOULD BE READ IN ITS ENTIRETY. IN PARTICULAR, YOU SHOULD READ AND UNDERSTAND THE INFORMATION PROVIDED IN THE \"IMPORTANT NOTICES\" SECTION.\n \n19 July 2018\n \nAllergy Therapeutics plc\n(\"Allergy Therapeutics\", the \"Company\" or the \"Group\")\n \nResults of Placing and Subscription\n \nAllergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, is pleased to announce the successful completion of the Placing and Subscription announced earlier today which was over-subscribed.\n \nA total of 40,000,000 new ordinary shares (the \"New Shares\") have been placed or subscribed for at a price of 26.5 pence per share (the \"Issue Price\") to raise £10.6 million (before expenses) for the Company. The New Shares being issued represent 6.7 per cent. of the issued ordinary share capital of the Company prior to the Placing and Subscription. The Issue Price represents a premium of 0.4 per cent. to the average mid-market closing price over the previous 60 trading days up to and including 18 July 2018, the last trading day before the announcement of the Placing and Subscription.\n \nManuel Llobet, Chief Executive Officer, stated: \n\"Allergy Therapeutics is now well positioned for a transformational period of growth both with our marketed products and our R&D pipeline. With this successful Placing and Subscription, we will expand our planned Phase III PQ Grass trial, scheduled to start in H2 2019, including a project to analyse pollen trends in the US to maximise the exposure of patients to grass pollen. We will also support t...